| Cystic MED15::TFE3 translocation renal cell carcinoma: histologic mimicker of multilocular cystic renal neoplasm of low malignant potential with review of the literature. | Cystic MED15::TFE3 translocation renal cell carcinoma: histologic mimicker of multilocular cystic renal neoplasm of low malignant potential with review of the literature.
Doytcheva K, Gallan AJ, Wang P, Wanjari P, Segal J, Antic T. | 05/31/2023 |
| Simple biochemical features underlie transcriptional activation domain diversity and dynamic, fuzzy binding to Mediator. | Simple biochemical features underlie transcriptional activation domain diversity and dynamic, fuzzy binding to Mediator.
Sanborn AL, Yeh BT, Feigerle JT, Hao CV, Townshend RJ, Lieberman Aiden E, Dror RO, Kornberg RD., Free PMC Article | 10/23/2021 |
| MED15 prion-like domain forms a coiled-coil responsible for its amyloid conversion and propagation. | MED15 prion-like domain forms a coiled-coil responsible for its amyloid conversion and propagation.
Batlle C, Calvo I, Iglesias V, J Lynch C, Gil-Garcia M, Serrano M, Ventura S., Free PMC Article | 08/14/2021 |
| MED15, transforming growth factor beta 1 (TGF-beta1), FcgammaRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma. | MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.
Elahi M, Rakhshan V., Free PMC Article | 12/5/2020 |
| In this article, we described MED15-TFE3 renal cell carcinoma (RCC), a rare gene subtype of Xp11 translocation RCCs, that was confirmed by FISH and RNA sequencing. The tumor demonstrated different morphological features and immunophenotypic characteristics with the cases reported in literatures, expanding our understanding on heterogeneity of MED15-TFE3 RCC. | A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Ye H, Qin S, Li N, Lin M, Xu Y, Li X., Free PMC Article | 04/25/2020 |
| MED15 does seem to play a tumour promoting role in the progression and metastatic spread of renal cell carcinoma | The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.
Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J, Syring I. | 09/1/2018 |
| MED15 overexpression arises during androgen deprivation therapy via hyper-activation of PI3K/Akt/mTOR signaling pathway in prostate cancer cells. | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Adler D, Perner S., Free PMC Article | 03/3/2018 |
| MED15 as a potential biomarker for head and neck squamous cell carcinoma | MED15: a potential biomarker for head and neck squamous cell carcinoma?
Offermann A, Adler D, Perner S. | 08/13/2016 |
| MED15 is differentially expressed in tumor-free testis and testicular germ cell tumors | Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.
Klümper N, Syring I, Offermann A, Adler D, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F., Free PMC Article | 05/28/2016 |
| MED15 overexpression is a clonal event during head and neck squamous cell carcinoma progression. | Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.
Adler D, Offermann A, Halbach R, Vogel W, Braun M, Kristiansen G, Bootz F, Wenzel J, Mikut R, Lengerke C, Reischl M, Schröck A, Perner S. | 12/12/2015 |
| these findings implicate MED15 in CRPC, and as MED15 is evolutionary conserved, it is likely to emerge as a lethal phenotype in other therapeutic-resistant diseases, and not restricted to our disease model. | MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
Adler D, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S. | 06/7/2014 |
| MED15 and PUM1 proteins with coiled-coil domains are potent enhancers of polyQ-mediated ataxin-1 protein misfolding and proteotoxicity in vitro and in vivo. | Identification of human proteins that modify misfolding and proteotoxicity of pathogenic ataxin-1.
Petrakis S, Raskó T, Russ J, Friedrich RP, Stroedicke M, Riechers SP, Muehlenberg K, Möller A, Reinhardt A, Vinayagam A, Schaefer MH, Boutros M, Tricoire H, Andrade-Navarro MA, Wanker EE., Free PMC Article | 12/22/2012 |
| The data identify PC2 as a novel PLAGL2-binding protein and important mediator of PLAGL2 transactivation. | Modulation of PLAGL2 transactivation by positive cofactor 2 (PC2), a component of the ARC/Mediator complex.
Wezensky SJ, Hanks TS, Wilkison MJ, Ammons MC, Siemsen DW, Gauss KA., Free PMC Article | 02/22/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesAn association study of PCQAP polymorphisms and schizophrenia.
Sandhu HK, Hollenbeck N, Wassink TH, Philibert RA, Sandhu HK, Hollenbeck N, Wassink TH, Philibert RA. Association study between CAG trinucleotide repeats in the PCQAP gene (PC2 glutamine/Q-rich-associated protein) and schizophrenia.
De Luca A, Conti E, Grifone N, Amati F, Spalletta G, Caltagirone C, Bonaviri G, Pasini A, Gennarelli M, Stefano B, Berti L, Mittler G, Meisterernst M, Dallapiccola B, Novelli G. | 03/13/2008 |
| SREBPs use the evolutionarily conserved ARC105 (also called MED15) subunit to activate target genes | An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis.
Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, DeBeaumont R, Saito RM, Hyberts SG, Yang S, Macol C, Iyer L, Tjian R, van den Heuvel S, Hart AC, Wagner G, Näär AM. | 01/21/2010 |
| Limited role of exon 7 PCQAP polymorphisms in the pathogenesis of schizophrenia. | An association study of PCQAP polymorphisms and schizophrenia.
Sandhu HK, Hollenbeck N, Wassink TH, Philibert RA, Sandhu HK, Hollenbeck N, Wassink TH, Philibert RA. | 01/21/2010 |
| TIG1 gene Silencing by promoter hypermethylation is associated with nasopharyngeal carcinoma | Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma.
Kwong J, Lo KW, Chow LS, Chan FL, To KF, Huang DP. | 01/21/2010 |
| Methylation of TIG1 in prostatic neoplasms correlates with methylation of the retinoic acid receptor beta gene. | Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene.
Zhang J, Liu L, Pfeifer GP. | 01/21/2010 |
| results suggest that TRIM11, with the ubiquitin-proteasome pathway, regulates ARC105 function in TGFbeta signaling | TRIM11 binds to and destabilizes a key component of the activator-mediated cofactor complex (ARC105) through the ubiquitin-proteasome system.
Ishikawa H, Tachikawa H, Miura Y, Takahashi N. | 01/21/2010 |
| The protein encoded by this gene was identified as ARC105, a 105kDa component of the Activator-Recruited Cofactor (ARC) that is involved in mediating gene activation by several classes of transcriptional regulators. | Composite co-activator ARC mediates chromatin-directed transcriptional activation.
Näär AM, Beaurang PA, Zhou S, Abraham S, Solomon W, Tjian R. | 10/3/2001 |